Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bourbonnais, IL
NPI
1407381171
Since 2017
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
100 Fitness Dr
Bourbonnais, IL, 60914
Phone (815) 936-8909
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
1,317 services
Medicare patients, 2024
298
Average age 71
Drug cost, 2024
$2.0M
4,040 prescriptions
Company payments, 2025
$104
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jabiz Behzadpour was code 99214 (office e&m - established), 737 times for 284 patients. In total Jabiz Behzadpour billed 1,317 services in 8 codes, and Medicare paid $60K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 737 | 284 | $64.74 | $48K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 281 | 188 | $12.39 | $3,480 |
| 95251 Test - Miscellaneous | Office | 269 | 102 | $24.47 | $6,581 |
| 99213 Office E&M - Established | Office | 11 | 11 | $22.23 | $245 |
By year: 2022 $17K for 253 services; 2023 $56K for 937 services; 2024 $60K for 1,317 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jabiz Behzadpour prescribed most often to Medicare patients was Levothyroxine Sodium, with 476 prescriptions and refills. In total Jabiz Behzadpour wrote 4,040 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 476 | 1,115 | 113 | $4,494 |
| Ozempic Semaglutide | 285 | 425 | 57 | $389K |
| Mounjaro Tirzepatide | 262 | 301 | 47 | $297K |
| Trulicity Dulaglutide | 205 | 301 | 44 | $280K |
| Metformin Hcl Er Metformin Hcl | 192 | 465 | 54 | $1,671 |
| Jardiance Empagliflozin | 168 | 358 | 47 | $204K |
| Synthroid Levothyroxine Sodium | 129 | 261 | 26 | $11K |
| Metformin Hcl Generic | 109 | 293 | 35 | $823 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 108 | 252 | 36 | $14K |
| Methimazole Generic | 105 | 286 | 27 | $861 |
| Tresiba Flextouch U-100 Insulin Degludec | 101 | 267 | 36 | $81K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 96 | 218 | 36 | $12K |
| Rosuvastatin Calcium Generic | 94 | 230 | 32 | $1,784 |
| Humalog Kwikpen U-100 Insulin Lispro | 88 | 181 | 35 | $27K |
| Novolog Flexpen Insulin Aspart | 80 | 182 | 27 | $19K |
Brand drugs: 2,395 claims; generic drugs: 1,270 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jabiz Behzadpour $104 ($104 in general payments such as food, travel and fees) from 5 companies. The largest payer was Sequel Med Tech, LLC with $27.45.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.